Keryx Biopharma is down more than 70 percent after one of its colon cancer drugs failed a late stage clinical trial, with Mark Tepper, Strategic Wealth Partners managing partner.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT